Upstream Bio Advances Verekitug Toward Phase 3 in Asthma
WALTHAM, Mass. — September 8, 2026 Upstream Bio, Inc. presented results from the Phase 2 VALIANT trial of verekitug...
Severe Asthma
Advertisement
Upstream Bio Sets Phase 3 Plans for Verekitug in Asthma
WALTHAM, Mass., Sept. 1, 2026 Upstream Bio, Inc. has announced its pivotal Phase 3 development plans for verekitug in...
Kinaset Doses First Patient in Phase 2b Frevecitinib Trial
BOSTON, MA, July 20, 2026 Kinaset Therapeutics announced that the first patient has been dosed in the Phase 2b...
GSK Wins China Approval for Exdensur in Severe Asthma
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
FDA Approves TEZSPIRE for Chronic Rhinosinusitis with Nasal Polyps
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
Advertisement
